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THE DESPERATE NEED TO INCLUDE PREGNANT WOMEN IN CLINICAL
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INTRODUCTION
The lack of human data available to make evidence-based decisions about
medicine taken during pregnancy has heightened awareness that pregnant women should
be included in biomedical research. 1 However, regulations, guidance, and the current
clinical trial landscape reflect an exclusionary approach to research. This paper explores
the lack of data available for pregnant women and healthcare practitioners to make
informed decisions about the safety of medication taken during pregnancy and changes
the federal government could make in an attempt to increase knowledge and data for
medications taken during a pregnancy.
The CDC estimates that 133 million Americans, almost one out of every two
adults, have at least one chronic illness.2 Many pregnant women have medical conditions
that require prescription medications, yet most drugs are approved without any clinical
research on their safe use during pregnancy. 3 These untested medications may treat
preexisting chronic conditions such as diabetes or seizures. 4 A study describing
medication use during pregnancy showed that the overall use has increased during the
past 30 years, and a majority of women took at least one prescription drug during
pregnancy. 5 The failure to understand the risks and benefits of medication use during
pregnancy can result in inadvertent exposure to the fetus, pregnancy termination, or

1

See infra notes 5–12, and accompanying text.
Chronic Diseases and Health Promotion, CDC.GOV,
http://www.cdc.gov/chronicdisease/overview/index.htm (last visited Mar. 11, 2014).
3
Pregnancy Research, CDC.GOV, http://www.cdc.gov/pregnancy/meds/research.html (last visited Mar. 11,
2014).
4
Pellavi Sharma, et al., An Innovative Approach To Determine Fetal Risk, 18 WOMEN’S HEALTH ISSUES,
226, 228 (2008).
5
Allen Mitchell et al., Medication use during pregnancy, with particular focus on prescription drugs:
1976-2008, 205 AM. J. OBSTETRICS & GYNECOLOGY 51.e1 (2011).
2
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alternatively, discontinuation in medication that may cause maternal or fetal harm.6
However, there is reluctance to conduct clinical research in pregnant women
because of ethical concerns. Pregnant women are a challenging population to conduct
research because of concerns of potential adverse effects of medication exposure to the
developing fetus.7 For example, it would be unethical to randomize pregnant women to
receive antidepressant drugs with unknown safety profiles. 8 Although there may be
situations when exclusion of pregnant women from research is justified, because of
ethical concerns, pregnant women are often reflexively excluded.9
A major concern for taking medication during pregnancy is the potential for fetal
adverse effects, or that drug pharmacokinetics are “commonly altered in pregnancy,
potentially affecting optimal dosing.”10 Except for the few products developed to treat
conditions unique to pregnancy, prescription drugs are not tested in pregnant women
prior to their approval, resulting in no data from controlled clinical trials.11 Risks and
benefits for the mother and fetus must carefully be weighed before prescribing, yet is a
challenge because of the scarcity of information available.12
Part I of this paper examines the historical background of women’s participation

6

Lydia E. Pace & Eleanor Bimla Schwarz, Balancing act: safe and evidence-based prescribing for women
of reproductive age, 8 J. WOMEN’S HEALTH 415, 416 (2012).
7
Meghan Coakley, et al., Dialogues on Diversifying Clinical Trials: Successful Strategies for Engaging
Women and Minorities in Clinical Trials, 21 J. WOMEN'S HEALTH 713 (2012).
8
Fabiano Santos et. al. Quality Assessment of Clinical Practice Guidelines for the Prescription of
Antidepressant Drugs During Pregnancy, 7 CURRENT CLINICAL PHARMACOLOGY 7, 8 (2012).
9
Kristine Shields & Anne Drapkin Lyerly, Exclusion of Pregnant Women From Industry-Sponsored
Clinical Trials, 122 AM. C. OBSTETRICIANS & GYNECOLOGISTS 1077 (2013).
10
Simon Thomas & Laura Yates, Prescribing without evidence – pregnancy, 74 BRIT. J. CLINICAL
PHARMACOLOGY 691, 692 (2012).
11
Content and Format of Labeling for Human Prescription Drug and Biological Products; Requirements for
Pregnancy and Lactation Labeling, 73 Fed. Reg. 30831-01, 30841 (proposed May 29, 2008) (to be codified
at 21 C.F.R. pt. 201).
12
Thomas & Yates, supra note 10 at 691; See also Paul Doering, et al., Review of pregnancy labeling of
prescription drugs: Is the current system adequate to inform of risks? AM. J. OBSTETRICS & GYNECOLOGY
333, 335 (2002).
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in clinical trials. Part II reviews the lack of evidence-based data for medication taken
during pregnancy. Part III assesses current regulations and guidance, and explains why
they are unsatisfactory. Part IV evaluates the current landscape of clinical research in
pregnant women in order to demonstrate the consequences of the lack of scientific data.
Part V recommends changes to federal regulations, or in the alternative, an incentivebased program to increase the enrollment of pregnant women in clinical research.
I. HISTORICAL EVOLUTION OF WOMEN AND CLINICAL RESEARCH – FROM COMPLETE
EXCLUSION TO AN EXCLUSIONARY APPROACH
A. History of Women As Research Subjects Before Guidelines & Congressional
Response to Exclude Women as Research Subjects
During the early nineteenth century, clinical trials depended upon the
experimentation of surgical procedures and methods on female American slaves,
followed by institutionalized populations and prisoners in the twentieth century. 13
Following the exposure of German brutalities during World War II, the Nuremberg Code
created the first internationally recognized standards for human research.14
In 1953, the Clinical Center at the National Institutes of Health established a
policy for the protection of human subjects. 15 For NIH clinical research, this policy
required informed consent of all subjects, and review and approval of research. 16
Following the NIH policies, Congress began to issue a number of laws and
standards for the protection of human subjects in research. In 1962, Congress passed the
Drug Amendments, which required that researchers testing investigational new drugs

13

See Ruth B. Merkatz & Suzanne W. Junod, Historical Background of Changes in FDA Policy on the
Study and Evaluation of Drugs in Women, 69 ACAD. MED. 703 (1994).
14
Id.
15
Joseph L. Breault, Protecting Human Research Subjects: The Past Defines the Future, 6 OCHSNER J. 15,
20 (2006).
16
Id.
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now had to obtain consent from research subjects.17
In 1974, Congress passed the National Research Act that mandated approval by
an IRB of human subjects research at any institution receiving DHHS funding.18 This
extended additional protections to research subjects of biomedical research, development,
and related activities involving, among other groups, fetuses, and pregnant women.19
However, in 1977 the FDA issued a guideline for drug development
recommending that women of childbearing potential be excluded from clinical drug
trials.20 This exclusion was applied broadly to any “premenopausal female being capable
of becoming pregnant.” 21 Although this exclusion was applicable to only women of
childbearing potential from early phases of drug trials, investigators and IRBs applied
this to all phases of drug trials.22
B. Shift Away from Excluding Women in Clinical Research
In 1986 NIH policy was changed to encourage the inclusion of women in research
to require a justification for exclusion of women as well as evaluate gender differences in
the future.23, 24 In 1990, the Women’s Health Equity Act was passed, and the Office for
17

Id.
Id.
19
Protection of Human Subjects, 45 C.F.R. § 46 (1975).
20
U.S. DEPT. OF HEALTH & HUMAN SERVS., FOOD & DRUG ADMIN., GENERAL CONSIDERATIONS FOR THE
CLINICAL EVALUATION OF DRUGS 7 (1977).
21
Id. See also Marianne Prout & Susan Fish, Participation of women in clinical drug trials of drug
therapies: a context for the controversies, 3 MEDSCAPE GEN. MED. 4 (2001) (noting that the exclusion from
drug trials also included all women using contraception, women with male partners, and single women; and
concluding that changes were prompted from public and political attention by the thalidomide tragedy
which resulted in over 10,000 children with birth defects worldwide to focus on drug approval processes).
22
Janet E. Shepard, Women and Health Research: Ethical and Legal Issues of Including Women in Clinical
Studies 272 JAMA 1467 (1994).
23
U.S. DEP’T OF HEALTH & HUMAN SERVICES, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF
HEALTH, OFFICE OF RESEARCH ON WOMEN’S HEALTH, ENROLLING PREGNANT WOMEN: ISSUES IN CLINICAL
RESEARCH (2011), available at http://orwh.od.nih.gov/resources/policyreports/pdf/ORWH-EPW-Report2010.pdf (noting that the historical research tragedies were due to the problem that research had not been
conducted to validate the use of the product).
24
See Maternal-Fetal Medicine Units (MFMU) Network, NICHD.NIH.GOV,
http://www.nichd.nih.gov/research/supported/Pages/mfmu.aspx (last visited May 6, 2014) (also in 1986,
18

4

Research on Women’s Health was established. 25 The NIH Revitalization Act of 1993
required that women must be included in all NIH-funded clinical research, unless a clear
and compelling rationale and justification established that inclusion is inappropriate with
respect to the health of the subjects or the purpose of the research. 26 Specifically, this
policy states that women of childbearing potential should not be routinely excluded from
participation in clinical research.27 The Act does not address research in pregnant women.
In 1993, the FDA lifted the 1977 guideline excluding women of childbearing
potential.28 This notice explained that subgroup-specific differences in response can arise
because of variations in a drug’s pharmacokinetics or pharmacodynamics. 29 The FDA
acknowledged that the removal of the prohibition on participation of women of
childbearing potential was consistent with congressional efforts to prevent unwarranted
discrimination against women. 30 While these guidelines removed the prohibition of
women in clinical trials, the FDA did not require female participation, nor did it address
potential benefits of including pregnant women. A lack of direction in combination with
advice to avoid pregnancy highlights the ethical dilemma of enrollment.31 The Food and
Drug Administration Modernization Act of 1997 mandated the review and development

the NIH Child Health and Human Development established the Maternal-Fetal Medicine Units Network to
response to the need for well-designed clinical trials within maternal-fetal medicine, specifically preterm
birth, with a focus to evaluate interventions for efficacy, safety and cost-effectiveness).
25
Id.
26
See NIH Policy and Guidelines on The Inclusion of Women and Minorities as Subjects in Clinical
Research, NIH.GOV, http://grants1.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm
(last visited Mar. 11, 2014).
27
Id.
28
Guideline for the Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs, 58
Fed. Reg. 39,406, 39,409–11 (July 22, 1993) [hereinafter the 1993 FDA GUIDELINE].
29
Id.
30
Id.
31
See 1993 FDA GUIDELINE, 58 Fed. Reg. 39,406 (the notice stated that precautions against becoming
pregnant and exposing a fetus should be taken by women participating in clinical trials).
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of guidance on the inclusion of women in clinical trials.32
In 1998, Congress passed a final rule that required New Drug Applications
(NDAs) to present effectiveness and safety data for important demographic subgroups,
specifically gender.33 This rule also required sponsors to tabulate in their annual reports
the numbers of subjects enrolled to date in clinical studies for drug and biological
products according to age group, gender, and race in Investigational New Drugs
(INDs).34
In 2014, the CDC launched an initiative, Treating for Two: Safer Medication Use
in Pregnancy, to improve the quality of data and information on medication use during
pregnancy. 35 The initiative seeks to expand medication safety research, evaluate
evidence, and educate women and healthcare providers.36
II. LACK OF EVIDENCE-BASED DATA FOR MEDICATION TAKEN DURING PREGNANCY IS A
GRAVE ISSUE
Pregnant women need safe and effective treatment options, but are left with a
severe lack of scientific data to support which option may be best during their pregnancy
due to legal and ethical concerns. Pregnant women are severely underrepresented in the
clinical research process, with the environment today as contrary to the core of social
32

See Participation of Females in Clinical Trials and Gender Analysis of Data in Biologic Product
Applications, FDA.GOV,
http://www.fda.gov/BiologicsBloodVaccines/DevelopmentApprovalProcess/InvestigationalNewDrugINDo
rDeviceExemptionIDEProcess/ucm094300.htm (last visited May 6, 2014) (explaining that the OWH
research project examined the extent to which females have been included in clinical trials for biological
products and to what extent the data from these studies have been analyzed and presented with respect to
gender. The FDA formed the “FDAMA women and minorities working group” with representatives from
the agency and the NIH to implement the section of the Act mandating the review and development of
guidance, as appropriate, on the inclusion of women in clinical trials).
33
Investigational New Drug Applications and New Drug Applications, 63 Fed. Reg. 6854-02 (Feb. 11,
1998) (to be codified at 21 C.F.R. pt. 312, 314).
34
Id.
35
Medications and Pregnancy, CDC.GOV, http://www.cdc.gov/pregnancy/meds/ (last visited Apr. 18,
2014).
36
Treating for Two, CDC.GOV, http://www.cdc.gov/pregnancy/meds/treatingfortwo/facts.html (last visited
Apr. 18, 2014).
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justice, where you treat others as dignified beings deserving of equal moral concern and
to view others as independent sources of moral worth and dignity. 37 This is not the
standard adhered to because pregnant women are not afforded the same attention and
rigorous research as other populations.38
The FDA Office of Women’s Health (OWH) advocates for the participation of
women in clinical trials to better understand the biologic basis for sex differences because
research has shown that sex as a variable contributes to differences in the safety and
efficacy of drugs, biologics, and devices. 39 Data show that women experience more
adverse drug reactions than men, and these reactions tend to be severe. 40 The 2001 GAO
report found that of ten prescription drugs taken off the market by the FDA due to
adverse events, eight were associated with greater health risks in women than men.41
In the past, most products approved by the FDA were studied exclusively in men
in order to obtain FDA approval.42 Pharmacological response may differ between men
and women, with an increase of identification of sex-gender pharmacodynamic
differences at a molecular level, however, these differences are understudied in women.43
For example, in 2013 the FDA cut the recommended dose of zolpidem in half for women,

37

Mary Foulkes, et al., Clinical Research Enrolling Pregnant Women: A Workshop Summary, 20 J.
WOMEN’S HEALTH 1429, 1432 (2011).
38
Id.
39
Understanding Sex Differences, FDA.GOV,
http://www.fda.gov/ScienceResearch/SpecialTopics/WomensHealthResearch/ucm131182.htm (last visited
Apr. 18, 2014).
40
Donald Mattison & Anne Zajicek, Gaps in Knowledge in Treating Pregnant Women, 3 GENDER MED.
169, 172 (2006).
41
Id.
42
Inside Clinical Trials: Testing Medical Products in People, FDA.GOV,
http://www.fda.gov/drugs/resourcesforyou/consumers/ucm143531.htm (last visited Apr. 18, 2014).
43
Flavia Franconi & Ilaria Campesi, Pharmacogenomics, Pharmacokinetics & Pharmacodynamics:
Interaction With Biological Differences Between Men And Women, 171 BRIT. J. PHARMACOLOGY 580
(2014).
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making this the only prescription in the U.S. with a different suggested dose by gender.44
Pregnancy further affects the ability of drug distribution, absorption, metabolism,
and elimination.45 Changes in the body’s physiology during pregnancy may require the
healthcare practitioner to increase or decrease a dose.46 Specifically, pregnancy places
different demands on the mother’s circulatory system because the uterus and placenta
require additional blood, increasing plasma volume faster than the blood cells increase.47
This increase of blood volume requires extra work from the heart and kidneys, leaving a
possibility that the drug may be excreted through a pregnant woman’s kidneys faster than
normal. 48 These changes also depend on the stage of pregnancy, so there may be
clinically important changes in drug concentrations between various trimesters of
pregnancy.49
A healthcare practitioner must blindly alter dosage for a pregnant woman because
research was not conducted in this population. A 2011 study of all medications approved
by the FDA from 1980 to 2010 found that 91% of the medications approved for use by
adults did not have sufficient data for the use and risks of medication taken during
pregnancy.50 With the well known fact that the human body responds differently during
pregnancy, it is unacceptable that this population is underrepresented in clinical research.
The largest study conducted on drug use during pregnancy is a 2004 retrospective
study that evaluated the experience of pregnant women, and concluded that 64% of

44

Lesley Stahl, Sex matters: Drugs can affect sexes differently, CBS NEWS (Feb. 9, 2014), available at
http://www.cbsnews.com/news/sex-matters-drugs-can-affect-sexes-differently/.
45
Mattison & Zajicek, supra note 40.
46
Michelle Meadows, Pregnancy and the Drug Dilemma, 35 FDA CONSUMER 16, 18 (2001).
47
Id.
48
Id.
49
Thomas & Yates, supra note 10 at 693.
50
MP Adam et al., Evolving knowledge of the teratogenicity of medications in human pregnancy, 157 AM.
J. MED. GENET. 175 (2011).
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pregnant women took a prescription drug before delivery.51 Researchers also concluded
“approximately one half of all pregnant women are prescribed drugs for which there is no
evidence of safety during pregnancy in humans or for which there is evidence of fetal risk
in animals or humans.”52 An additional complication is that studies performed in animals
are of limited value because adverse events may be species specific. 53 This further
demonstrates the need to change the way research is conducted in order to gather data for
prescription medications that are taken during pregnancy. A 2010 study showed that over
the last three decades, first trimester use of prescription medicine increased by more than
60%, and the use of four or more medications more than tripled.54 This study suggests
there is also an increase of practitioners prescribing medications in addition to taking
medication during pregnancy without pharmacokinetic data.
III. CURRENT REGULATIONS AND GUIDANCE
DHHS regulations governing the protection of human subjects in research contain
five subparts. Subpart A is the basic set of protections for all human subjects of research
conducted or supported by HHS; this subpart is known as the Common Rule, because it
has been adopted in identical form by 15 federal departments and agencies. The DHHS
regulations also contains subparts B, C and D, which provide added protections for
specific vulnerable groups of subjects, including pregnant women, prisoners and children,
and subpart E, which governs IRB registration.55
The FDA is a DHHS agency that regulates clinical investigations of drugs,

51

Susan E. Andrade et al., Prescription drug use in pregnancy, 191 AM. J. OBSTETRICS & GYNECOLOGY
398 (2004).
52
Id.
53
Thomas & Yates, supra note 10 at 692.
54
Mitchell et al., supra note 5.
55
Regulations, HHS.GOV, http://www.hhs.gov/ohrp/humansubjects/index.html (last visited May 6, 2014).
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biological products and medical devices and has adopted and codified subparts A and D
as FDA human subject protection regulations. 56 The FDA has not adopted regulations
outlining special protections for pregnant women, fetuses or prisoners.57
A. DHHS 45 C.F.R. Subpart B: Protection of Human Subjects
Under subpart B, pregnant women may participate in research:58
a. Where scientifically appropriate, preclinical studies, including studies on
pregnant animals and clinical studies, have been conducted and provide
data for assessing potential risks to pregnant women;
b. The risk to the fetus is caused solely by interventions or procedures that
hold out the prospect of direct benefit for the woman or fetus; or, if there
is no prospect of benefit, the risk to the fetus is not greater than minimal;
c. Any risk is the least possible for achieving the objectives of the research;
d. If the research holds out the prospect of direct benefit to the pregnant
woman, the prospect of a direct benefit both to the pregnant woman and
the fetus, or no prospect of benefit for the woman nor the fetus when the
risk to the fetus is not greater than minimal, and her consent is properly
obtained;
e. If the research holds out the prospect of direct benefit solely to the fetus
then the consent of the pregnant woman and the father is properly
obtained, except if the father is unable to consent because of
unavailability, incompetence, or temporary incapacity or the pregnancy
resulted from rape or incest.
f. Each individual providing consent here is fully informed regarding the
reasonably foreseeable impact of the research on the fetus;
g. Pregnant children must assent and obtain permission in accord with
subpart D;
h. No inducements, monetary or otherwise, will be offered to terminate a
pregnancy;
i. Individuals engaged in the research will have no part in any decisions as to
timing, method, or procedures used to terminate a pregnancy.
j. Individuals engaged in research will have no part in determining viability.
The aforementioned regulations provide IRBs ten requirements for selecting
pregnant women in clinical research. First, the regulations require a prerequisite to

56

Id.
Comparison of FDA and HHS Human Subject Protection Regulations, FDA.GOV,
http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/educationalmaterials/ucm11291
0.htm (last visited May 6, 2014).
58
45 C.F.R. § 46.204.
57
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research to conduct studies on non-pregnant women first. This condition is that
preclinical studies must be conducted to provide data for an assessment of potential risks
to pregnant women and fetuses. A concern is that a precondition of preclinical studies on
non-pregnant women is that pregnant women are neglected or excluded from research.
This requirement is to ensure that safety trials are ethical and do not expose the fetus to
potential adverse harms. The Department agreed and noted that preclinical and clinical
studies are required only when scientifically appropriate.59
Second, terminology in the regulations requires IRBs to determine the meaning of
minimal risk and direct benefit. The regulations require that if there is no prospect of
benefit from the trial, the risk to the fetus must not be greater than minimal. This means
that the risk to the fetus is the least possible risk for achieving research objectives and any
greater risk must be a direct benefit to the fetus or woman. However, there is a great
problem amongst IRBs in determining the meaning of this phrase because “no more than
minimal risk is extremely vague and interpreted by different IRBs in radically different
ways.”60 Additionally, IRBs are also left to determine the meaning of direct benefit, and
whether there is a high probability of direct benefit, or if the probability is even relevant.
Subpart B grants IRBs the opportunity and the authority to ensure the adequacy of
informed consent and protections by imposing additional requirements and monitoring
the research or consent process. 61 The Department recognizes and encourages paternal
involvement in decisions affecting the pregnant woman and fetus prior to delivery,

59

Protection of Human Research Subjects, 66 Fed. Reg. 3878-01, 3880 (Jan. 17, 2001) (to be codified at 45
C.F.R. pt. 46).
60
Regulatory Fixes And Clarification Needed For Involving Pregnant Women In Clinical Trials, 18 NO. 5
GUIDE TO GOOD CLINICAL PRACTICE NEWSL. 10 (Feb. 2011).
61
Protection of Human Research Subjects, 66 Fed. Reg. 3878-01 at 3880.
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although there is a concern that the paternal consent is a barrier. 62 However, the
regulations note that consent is not needed if the father is unavailable. Ultimately, the
Department concluded that the decision-making authority for research participation of the
pregnant woman or fetus prior to delivery should rest with the pregnant woman.63
B. FDA and the Enrollment of Pregnant Women in Clinical Trials
The DHHS Protection of Human Subjects Regulations categorizes pregnant
women as a vulnerable population and contains rules and guidance for research with
pregnant women. While DHHS has special subparts relating to research for vulnerable
populations, such as prisoners, and pregnant women, the FDA does not have comparable
provisions for these populations.64
1. FDA Tools to Ensure Demographic Data Analysis
In 1998, the FDA amended its regulations to require effectiveness and safety data
for demographic subgroups, specifically gender, age and racial subgroups.65 Therefore,
the FDA is permitted to place a clinical hold on one or more studies under an IND if a
sponsor proposes to exclude gender from participation in an investigation only because of
risk or potential risk from the use of an investigational drug.66 Furthermore, in 2007, the
FDA required that prescription drug products must contain specific information about use
in specific populations in the contents of drug labeling. 67 In a 2013 FDA report, a
working group found that the FDA’s internal policies, procedures and regulations
facilitate the assessment of demographic subgroup information included in marketing
62

Id.
Id.
64
Comparison of FDA and HHS Human Subject Protection Regulations, FDA.GOV,
http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/educationalmaterials/ucm11291
0.htm (last visited May 6, 2014).
65
See 21 CFR §§ 312, 314.
66
21 C.F.R. § 312.42.
67
21 C.F.R. § 201.56(7).
63
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applications.68 The FDA can communicate demographic information to the public after
marketing approval through a variety of mechanisms, including product labeling, publicly
posted clinical reviews, consumer updates, safety alerts, and label changes.69
While the FDA shifted their approach from excluding women in research to
allowing women, the agency does not actively require or regulate research in pregnant
women. The agency requires IND applications to include reports by sex; however the
breakdown in this data is only male and female. The FDA fails to make an affirmative
requirement to collect data on any pregnant woman involved in a clinical trial.
Additionally, the FDA issued draft guidance for a basic framework for designing
and conducting clinical studies in pregnant women, 2004 Guidance for Industry
Pharmacokinetics in Pregnancy - Study Design, Data Analysis, and Impact on Dosing
and Labeling. The draft guidance provides recommendations to sponsors on how to
assess the influence of pregnancy on the pharmacokinetics and the pharmacodynamics of
drugs, as well as recommendations for investigators and researchers about issues to
consider when designing and conducting PK studies in pregnant women.70 The guidance
adopts 45 C.F.R. § 46.204, stating that
Pregnant women may be involved in PK studies if the following
conditions are met: preclinical studies, including studies on pregnant
animals, and clinical studies, including studies on nonpregnant women,
have been conducted and provide data for assessing potential risk to
pregnant women and fetuses; and the risk to the fetus is not greater than
minimal and the purpose of the research is the development of important

68

U.S. DEPT. OF HEALTH & HUMAN SERVS., FOOD & DRUG ADMIN., Collection, Analysis, and Availability
of Demographic Subgroup Data for FDA-Approved Medical Products (2013) available at
http://www.fda.gov/downloads/regulatoryinformation/legislation/federalfooddrugandcosmeticactfdcact/sig
nificantamendmentstothefdcact/fdasia/ucm365544.pdf.
69
Id.
70
CENTER FOR DRUG EVALUATION & RES., U.S. FOOD & DRUG ADMIN., DRAFT GUIDANCE FOR INDUSTRY:
PHARMACOKINETICS IN PREGNANCY –STUDY DESIGN, DATA ANALYSIS, AND IMPACT ON DOSING AND
LABELING (Oct. 29, 2004) [hereinafter 2004 FDA DRAFT GUIDANCE].
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biomedical knowledge which cannot be obtained by any other means.71
The FDA acknowledges that the definition of minimal risk is broad and states that “fetal
risk is considered minimal when the estimated risk to the fetus is no more than that from
established procedures routinely used in an uncomplicated pregnancy or in a pregnancy
with complications comparable to those being studied.”72 The guidance anticipates that
most of the studies in pregnant women will occur postmarketing from pregnant women
who have already been prescribed the drug.73
This draft guidance does not encourage or incentivize industry or researchers to
actively enroll pregnant women in studies. Clear agency guidance with affirmative
actions items, such as the mandatory collection of postmarketing data or an active
approach to recruitment, would enable the FDA to increase enrollment.
2. FDA Tools to Collect Data on Medications Taken During Pregnancy
The FDA published pregnancy exposure registry guidelines in 2002 and 2005, to
encourage the collection of and to facilitate the analysis and interpretation of data
regarding medication exposure during pregnancy.74 These pregnancy exposure registries
are a prospective observational study that examines fetal risk from medication exposure
during pregnancy in which the enrollment criteria includes pregnant women already
taking the medication where fetal outcomes have not yet been ascertained.75
When drug safety data is collected after a drug is licensed, problems may arise,
such as the “lack of information about confounding factors, maternal adherence to
71

Id.
Id.
73
Id.
74
See Sharma supra, note 4 at 228 (discussing the 2002 Guidance for Industry: Establishing Pregnancy
Exposure Registries and the 2005 Reviewer Guidance: Evaluating the Risks of Drug Exposure in Human
Pregnancies).
75
Id.
72
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prescribed medication, use of over-the-counter medicines…and difficulty in evaluating
longer term effects.”76 The FDA has not made pregnancy exposure registries mandatory
for manufacturers to track data, but left this responsibility to the pregnant women taking
the drug.77 The agency explicitly states “since drug companies can’t test medicine on
pregnant women, they may have little or no information about how these medicines could
affect a woman or her fetus. Pregnancy registries are the best way to learn and to help
women decide about taking medicines.” 78 The FDA had the opportunity to require
industry to take a proactive approach to this research but failed to make this a
requirement.
C. Non-binding Guidance Includes Pregnant Women in Clinical Research
International and professional committees provide clearer guidance to include
pregnant women in research. There is an opportunity to shift the paradigm from
excluding pregnant women in clinical research to a presumption that pregnant women are
eligible for relevant research.
The Council for International Organizations of Medical Science guidelines,
International Ethical Guidelines for Biomedical Research Involving Human Subjects,
relate mainly to ethical justification and scientific validity of research. 79 However, there
is an explicit provision for pregnant women as research participants, which states
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Pregnant women should be presumed to be eligible for participation in
biomedical research. Investigators and ethical review committees should
ensure that prospective subjects who are pregnant are adequately informed
about the risks and benefits to themselves, their pregnancies, the fetus and
their subsequent offspring, and to their fertility. Research in this
population should be performed only if it is relevant to the particular
health needs of a pregnant woman or her fetus, or to the health needs of
pregnant women in general, and, when appropriate, if it is supported by
reliable evidence from animal experiments, particularly as to risks of
teratogenicity and mutagenicity.80
CIOMS justification of research involving pregnant women recognizes that it is
complicated by the fact that it may present risks and potential benefits to two beings, the
woman and the fetus, as well as to the person the fetus is destined to become. 81 The
commentary states that special safeguards should be established to prevent undue
inducement to pregnant women to participate in research in which interventions hold out
the prospect of direct benefit to the fetus. 82 Finally, the commentary states that
investigators should include in protocols on research on pregnant women a plan for
monitoring the outcome of the pregnancy with regard to both the health of the woman
and the short-term and long-term health of the child.83 This guidance is clear in stating
that pregnant women should be presumed eligible for participation in clinical research. A
presumption of eligibility will deter the fear of the overbroad presumption of ineligibility.
A 2005 guideline from the European Medicines Agency, Guideline on the
Exposure to Medicinal Products During Pregnancy, proposed active surveillance for the
collection of post-authorization data in pregnancy.84
The American Congress of Obstetricians and Gynecologists issued a 2007
80
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Committee Opinion designed to provide reasonable guidelines for research involving
women.85 This opinion affirmatively states:
All women should be presumed to be eligible for participation in clinical
studies. The potential for pregnancy should not automatically exclude a
woman from participating in a clinical study, although the use of
contraception may be required for participation. Inclusion of women in
clinical studies is necessary for valid inferences about health and disease
in women. The generalization to women of results from trials conducted in
men may yield erroneous conclusions that fail to account for the biologic
differences between men and women.86
ACOG’s Committee on Ethics affirms both the need for women to serve as participants
in research and the obligation for researchers, IRBs, and others reviewing clinical
research to evaluate the potential effect of proposed research on women of childbearing
potential, pregnant women, and the developing fetus.87
ACOG explicitly states that pregnancy should not automatically exclude a woman
from participating in a study. However, as Part IV of this paper examines, most studies
categorize pregnant women as part of the exclusionary criteria. ACOG’s non-binding
guidance recognizes the need to include women in studies but falls short of the
presumption of eligibility for pregnant women to participate.
IV. TODAY’S ENVIRONMENT: BURDENS TO OVERCOME TO INCREASE ENROLLMENT OF
PREGNANT WOMEN IN CLINICAL RESEARCH
The current clinical trial landscape does not demonstrate an inclusionary approach
of pregnant women in clinical research. Despite the need to include pregnant women in
drug trials, there is not a big push to enroll this population.88 For example, only one drug,
Makena, has been approved by the FDA for pregnancy indications in the past five
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years.89
A. Clinical Trials Do Not Actively Recruit Pregnant Women
Using the NIH database for clinical trials, an analysis of Phase I, II and III studies
for both industry and NIH or government funded including “pregnant” supports the gross
underrepresentation of pregnant women in research. 90 Out of the 166,199 studies
registered with ClinicalTrials.gov, there are 1,686 studies that include the term
“pregnant.” 91 For trials sponsored by the NIH or other government funding, there are
currently 71 studies in Phase I that include the term “pregnant,” 65 studies in Phase II,
and 97 studies in Phase III. 92 For trials sponsored by industry, there are currently 9
studies in Phase I that include the term “pregnant,” 14 studies in Phase II, and 29 studies
in Phase III. 93 However, these numbers overstate studies including pregnant women
because the search returned studies in which “pregnant” was listed as an exclusion
criteria. The few drug and biologic studies actively recruiting pregnant women were for
HIV, influenza, malaria or a pregnancy related conditions.
According to this analysis using the NIH database, only two trials from NIH
sponsors actively recruited pregnant women for a condition other than HIV, influenza,
malaria or pregnancy related condition. The NIH or government funded studies yielded
only two trials of interest. A Phase I vaccine trial was conducted in 48 pregnant women
and 32 non-pregnant women to look at the safety and immunogenicity of a combination
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vaccine. 94 A Phase III trial for diabetic pregnant women actively recruited pregnant
women with insulin-resistant diabetes mellitus, yet excluded pregnant women with type-I
diabetes.95 Noticeably absent were studies involving depression, asthma or hypertension.
The second interesting finding from the NIH database is that, out of the 52 studies
containing the term “pregnant” in industry sponsored studies, zero studies actively
recruited pregnant women for a condition other than HIV, influenza, malaria, or
pregnancy related condition. 96 Pfizer and Cedars-Sinai Medical Center terminated a
study, which recruited both men and women for the treatment of anxiety disorder. 97
While this study excluded pregnant women, the study required “partners of male
participants who become pregnant during the course of the study to participate in order to
collect safety information and understand the effects, if any, that the investigational drug
may have on her pregnancy or the fetus.”98 Here, industry is excluding pregnant women
from studies and failed to actively recruit pregnant women for chronic condition research.
A 2012 report found that in the past two years, 264 drug trials have been
registered and or performed specifically in pregnant women.99 This report analyzed the
ClinicalTrials.gov database with the keyword “pregnancy” and searched the abstracts
from annual meetings from five organizations.100 However, the report found that it was
impossible to determine how many of the trials were being performed on investigational
drugs or where the funding came from because of inconsistent data between the website
94
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and the organizations.101 But the report was consistent in finding that the most common
treatment objectives of studies in pregnancy were antibiotic and anti-infective agents,
including hepatitis, HIV and malaria, as well as preterm birth prevention, vitamin and
nutrition supplements, diabetes and gestational diabetes, and labor induction.102
Furthermore, a 2013 study concluded that out of 558 Phase IV studies, only five,
or 1%, were designed specifically for pregnant women.103 This study also found that 95%
of qualified studies explicitly excluded pregnant women, suggesting the exclusion to be
common practice.104 These results demonstrate that industry is not conducting research
on pregnant women in Phase IV studies. This information highlights the importance of
changing the approach to clinical research in pregnant women.
B. Drug Case Studies Associated with Birth Defects and Industry’s Response
Physicians may fail to prescribe drugs during pregnancy because of the lack of
data for drug safety, efficacy and dosage, or the fear of the unknown risk to the fetus. The
failure to treat chronic illnesses such as depression, diabetes or asthma may cause
significant harm to both the mother and the fetus. Pregnant women and physicians are
faced with the challenging decision whether to use a medication without sufficient safety
data or to stop medication. Researchers are faced with an ethical dilemma of when to
enroll pregnant women in clinical research. Manufacturers lack an incentive to enroll
pregnant women in research, even if safety in pregnant women may be a known issue.
The use of medicines in pregnancy is increasing due to the increasing rates of
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maternity in older women. 105 There is a significant prescribing of drugs known to be
associated with fetal risks, with 1-4% of women being prescribed medicines considered
contraindicated.106
This section discusses birth defects associated with drugs when taken during
pregnancy and assesses whether the FDA and manufacturer responded appropriately.
1. Paxil Case Study: Is it Safer to take an Antidepressant or Discontinue
Medication During Pregnancy?
In the case of depression, a pregnant mother is faced with the hard decision
whether to stop using an antidepressant, or to continue using the antidepressant despite
manufacturer warnings about possible fetal harm. Clear guidance for which treatment
option is best for a pregnant mother suffering from a mental disorder that requires
medication is nonexistent.
Antidepressants are widely prescribed for major depression and other psychiatric
disorders and are considered the primary treatment for moderate to severe depression,
although their effectiveness and safety during pregnancy have been studied
infrequently.107 In pregnant women with depression, antidepressants have been shown to
reduce symptoms, however discontinuation has been “associated with increased risk of
antenatal depressive relapses.108 Furthermore, untreated gestational depression has been
associated with “pre-eclampsia, preterm delivery, low birth weight, sudden infant death,
developmental delay in offspring, post-partum depression and maternal suicide.”109 For
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many years, selective serotonin reuptake inhibitors (SSRIs), “the most commonly
prescribed antidepressants, were regarded as safe for use in pregnancy.”110
In 2004, the FDA issued public health advisories about the risk of perinatal
complications with SSRIs and other antidepressants.111 These warnings were “prompted
by increasing reports of adverse neonatal outcomes associated with maternal
antidepressant use including potential risk for cardiovascular malformations.”

112

However, the regulatory warnings did not advise against the use of antidepressants during
pregnancy nor recommend antidepressant discontinuation.113
The FDA first approved Paxil, an SSRI to treat depression, in 1992.114 However,
Paxil has been associated with a number of birth defects. In 2005 the manufacturer of
Paxil told physicians that preliminary study results suggested an increased risk of
congenital malformations associated with the use of Paxil during early pregnancy as
compared with other antidepressants.115 The prescribing information for Paxil CR states
that there are no adequate and well-controlled studies in pregnant women, and it should
be used during pregnancy only if the potential benefit justifies the potential risk to the
fetus. 116 However, lawsuits charge that the manufacturer deliberately withheld what it
knew about Paxil’s dangers to developing fetuses. 117 The manufacturers motion to
dismiss various products liability claims was granted with respect to all claims, except the
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failure-to-warn. 118 Specifically, after using Paxil while pregnant, plaintiff's infant
daughter died sixteen days after birth from a congenital heart defect.119 After the infant's
death, the manufacturer revised the warning label to indicate that there were no adequate
studies of the drug in pregnant women and that one study indicated an increased risk of
congenital cardiovascular malformations from use of paroxetine.120
The failure to gather consistent data about safety of antidepressant use during
pregnancy is a contributing factor to the well-known SSRI birth defects and is an
example of the need for evidence-based data. With this data, consistency in safety for
depression and pregnancy will be uniform.
2. Accutane Case Study: The FDA’s Response to Accutane Birth Defects
Accutane (isotretinoin) is a highly effective treatment for severe recalcitrant
nodular acne, but is known to cause serious birth defects when pregnant women use the
drug.121 The manufacturers of Accutane and the FDA implemented a risk management
program to educate women about the risk of becoming pregnant while taking this drug.122
The iPLEDGE program is to prevent the use of Accutane during pregnancy and in order
to obtain the drug, patients must register with iPLEDGE, and comply with a number of
requirements that include completing an informed consent form, obtaining counseling
about the risks and requirements for safe use of the drug, and, for women of childbearing
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age, complying with necessary pregnancy testing.123 This risk management program is an
example of a controlled data collection environment that will decrease birth defects.
3. Depakote ER Case Study: Abbott’s Unwillingness to Conduct Research in
Pregnant Women
The FDA approved Depakote for marketing in 1983. 124 In 1996, Depakote
(divalproex sodium), manufactured by Abbott Laboratories, was approved for the
treatment of epilepsy and migraine headaches.125 In 2000, Depakote ER was approved for
the prevention of migraine headaches in adults.126 The FDA warned Depakote ER had
been associated with birth defects, specifically, spina bifida.127
In May 2013, the FDA released a Drug Safety Communication for Depakote ER,
which stated a recent study showed children exposed to this class of drugs while their
mothers were pregnant had decreased IQs. 128 This warning also stated the FDA will
advise manufacturers to change the pregnancy category129 for migraine use from “D” to
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“X.” 130 According the to the prescribing information, Depakote ER is currently
pregnancy category D for epilepsy and for manic episodes associated with bipolar
disorder, and category X for prevention of migraine headaches. 131 The different
pregnancy categories for the same product will likely lead to confusion amongst
prescribers and women.
The FDA’s communication of contraindication, category X, for prevention of
migraines in pregnant women does not provide clear guidance because it only warns that
pregnant women taking this medication should not stop since stopping suddenly may
cause life-threatening problems to the woman or baby.132 The FDA stated that it is not
known if there is a specific time period for harm or when the exposure may be considered
to have less risk for decreased IQ in children.133 This communication does not discuss the
risks associated with Depakote ER for the original epilepsy indication.
The Depakote ER fetal risk knowledge gap from the approval to the subsequent
black box warnings is alarming for three reasons. First, the method by which the data for
fetal risk were obtained compared to the time on the market is a concern. Pregnancy
registry data134 in combination with drug safety warnings suggest Abbott did not engage
in any proactive studies to determine the safety of Depakote ER in pregnant women.135
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The second observation is the failure to require a mandatory exposure registry.136
The prescribing information states that physicians “should encourage patients to enroll in
the registry in order to collect information on the effects of in utero exposure to
Depakote.” 137 Abbott is not required to participate in the registry nor conduct further
surveillance on pregnant patients taking Depakote ER.
The third observation is Abbott’s affirmative exclusion of pregnant women from
clinical trials. According to the NIH database, Abbott sponsored a Phase III open label
study in 2005 to determine the safety of Depakote ER in adolescents. 138 In order to be
eligible for the study, the participant had to be male, or a non-pregnant, non-lactating
female. 139 The NIH database yielded zero studies including pregnant women and
divalproex sodium.
4. Lessons Learned: If Industry, the Government and Manufacturers Aligned on
Requiring Research in Pregnant Women, Could Birth Defects Decrease?
Paxil, Accutane, and Depakote ER all caused serious birth defects in some women
who took these prescriptions during pregnancy. Ethical concerns regarding the safety of
medication on fetuses have been a driving force in the exclusion of pregnant women from
clinical studies. However, the risk that should be considered is whether to expose a
consenting pregnant woman to medication in a closely monitored research setting, instead
of exclusion because of an unknown fear. If data were collected earlier, documentation of
about this risk in a June 2011 Drug Safety Communication, but the product was approved for the
prevention of migraines in 2000, Abbott was aware of possible side effect of spina bifida taken during
pregnancy, but did not publish information regarding malformations or lower IQ scores. It was not until
eleven years later that the FDA released a safety announcement that was based on the results of an
epidemiological study, which was not an Abbott study.
136
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known birth defects would decrease medication exposure and increase education.
For example, when data became available about birth defects associated with
Paxil, there was an opportunity to proactively obtain birth defect data. The FDA had the
ability to require postmarketing surveillance as a condition of approval for Paxil in
pregnant women.140 Furthermore, GSK did not provide the public with this information.
Contrast Paxil to Accutane, where the FDA took a proactive role in ensuring that
women do not become pregnant while taking the drug because of known serious birth
defects. Additionally, if the manufacturer was required to collect pregnancy exposure
data on Accutane before the staggering number of reported birth defects, there is a higher
probability for a lower number of birth defects due to a proactive role.
Lastly, in the case of Abbott, they failed to take a proactive approach to better
understand known risks of exposure during pregnancy. Depakote was already associated
with birth defects, but neither additional studies nor postmarketing surveillance on
exposure were conducted.
V. IMPROVE CLINICAL RESEARCH PROTOCOLS TO INCREASE ENROLLMENT OF PREGNANT
WOMEN IN STUDIES
The harms of inadequate clinical research fall enormously on pregnant women,
their fetuses, and children exposed to medication in utero. It is clear that research does
not actively recruit pregnant women for chronic conditions such as diabetes, depression
or hypertension. The result of the failure to study medication in pregnant women
negatively impacts society, industry, and the ability to enroll pregnant women in studies.
First, this recommendation addresses the ability to increase enrollment of
140
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pregnant women in clinical trials by examining different approaches agencies may adopt.
The four approaches suggest the least inclusive to most inclusive participation of
pregnant women in research: (1) agency collaboration, (2) notice and comment period for
proposed rulemaking, (3) incentive based program, and (4) mandatory requirements.
A. OWH & ORWH Collaboration to Develop Awareness, Education & Guidance
With the education of healthcare professionals, researchers and pharmaceutical
manufacturers, there is an ability to increase the enrollment of pregnant women in clinical
trials. The FDA’s OWH and the NIH’s Office of Research on Women’s Health (ORWH)
must work collaboratively to issue updated guidance to communicate the importance of
increasing the enrollment of pregnant women in clinical research.
First, the OWH 141 and ORWH 142 must update their mission and messaging to
include pregnant women, not only women to eliminate the exclusionary approach of
pregnant women in clinical studies. Noticeably absent from both organizations is
pregnant women advocacy for both health and research.
Second, the OWH and ORWH must educate stakeholders and increase their
awareness about the importance of pregnant women in clinical research. Awareness can
be achieved by the publication of research, education, and guidelines. A collaboration of
stakeholders to gather data must include guidance and decision makers, regulators,
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payers, providers, researchers, IRBs, ethics committees, patients, and the public.143
Third, the OWH and ORWH must publish updated policies to increase awareness
among the general public and key stakeholders. The FDA is holding a public meeting in
May 2014 on study methodologies to evaluate the safety of drugs during pregnancy.144
The FDA must also update their 2012 policy, Successful Strategies for Engaging
Women and Minorities in Clinical Trials, because this policy does not address engaging
pregnant women, but only offers strategies for diversity in trials by the recruitment of
female physicians, trust, education through awareness, and community involvement.145
B. Notice and Comment Period for Rulemaking to the Common Rule
A notice of proposed rulemaking should be communicated about changes to the
Common Rule. This notice will allow for public comment and require an answer and
explanation from the OHRP. The proposed changes should remove pregnant women from
the vulnerable population category and the paternal consent requirement in order to
remove barriers to enrollment. The proposed changes should also adopt the FDA’s
guidance definition of minimal risk to the fetus in order to further clarify the term
minimal risk, obtain public comment, and allow for OHRP to respond.
First, the regulations must remove pregnant women from the vulnerable
population category. The regulations define criteria for IRB approval of research as
“when some or all of the subjects are likely to be vulnerable to coercion or undue
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influence…additional safeguards have been included in the study to protect the rights and
welfare of these subjects.” 146 It is not appropriate to categorize pregnant women as
vulnerable to coercion or undue influence. Coercion is defined as compulsion by physical
force or threat of physical force, and undue influence is defined as the improper use of
power in a way that deprives a person of free will and substitutes another's objective. 147
To group all pregnant women as a vulnerable population that is susceptible to physical
force or subject to a deprivation of free will is inexcusable. The difference between
pregnant women and the other vulnerable populations falls under decision-making
ability. One cannot reasonably believe that pregnant women, as a whole, lack the ability
to make their own autonomous decisions because they are vulnerable in society.
Second, the regulations should remove the paternal consent requirement. The
Department recognizes and encourages paternal involvement in this decision making
process, nevertheless, in some cases the father’s consent is a barrier to participation in
research.148 General comments to the final rule for subpart B state “the recommendations
of the National Task Force on AIDS Drug Development, the Presidential Advisory
Council on HIV/AIDS, and the IOM Committee were unanimous that the consent of the
father should not be a condition of the participation of a pregnant woman in research.”149
The final rule also stated that some commenters described specific trials in which
pregnant women were unable to participate in potentially beneficial research because
they could not get paternal consent.150 The informed consent process deems the woman
as sufficient to make her autonomous decision to engage in research and the paternal
146
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consent should be removed due to it being a barrier.
Lastly, the Department should further define minimal risk. In FDA guidance, they
acknowledge the definition of minimal risk is broad and state “fetal risk is considered
minimal when the estimated risk to the fetus is no more than that from established
procedures routinely used in an uncomplicated pregnancy or in a pregnancy with
complications comparable to those being studied.”151 Therefore, regulations should adopt
the FDA’s proposed definition of minimal risk in order to encourage researchers and
IRBs to be more inclusive in enrolling pregnant women.152
C. Create Incentive Based Program to Increase Enrollment of Pregnant Women
Congress should expand the six-month pediatric patent exclusivity regulation to
pregnant women. This would incentivize manufacturers to conduct studies in pregnant
women, similar to the studies conducted in the pediatric population.
Congress awards six months of patent exclusivity in return for conducting
pediatric studies as a marketing incentive to manufacturers.153 The FDA requires that the
manufacturer conduct the trials in order to receive the patent exclusivity for marketing.154
The exclusivity is granted for conducting a valid study even if the information collected
by the manufacturer does not demonstrate an effect or difference.155
The FDA may develop, prioritize, and publish a list of approved drugs for which
additional pediatric information may produce health benefits in the pediatric
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population.156 To determine the drugs on the list, the FDA used several criteria, consulted
with experts, and made the draft list available for public comment. 157 The criteria158 and
therapeutic category159 were central to determine patent exclusivity.
There is a similar opportunity to increase the enrollment of pregnant women in
research by creating a patent exclusivity incentive for manufacturers to conduct studies in
pregnant women. Researchers are reluctant to conduct studies in pregnant women
because of ethical concerns for adverse effects of medication exposure to the developing
fetus.160 If the FDA expands 21 U.S.C. § 355a to research in pregnant women, the agency
can educate researchers for when it is ethically appropriate to conduct research.161
Pharmaceutical manufacturers have taken advantage of patent exclusivity for new
pediatric drugs. As of February 2014, the FDA granted pediatric exclusivity for 216
pediatric studies.162 An analysis of the 199 drugs that were granted exclusivity shows the
predominance of top pharmaceutical companies receiving exclusivity periods for
drugs.163
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These data suggest that top manufacturers were able to meet requirements for
research in pediatric populations when there was a potential for health benefit. Similar to
pediatric research, manufacturers may choose when to conduct trials in pregnant women.
D. Mandatory Requirements to Increase Enrollment of Pregnant Women in
Clinical Research
Congress, the FDA and the NIH have the ability to amend laws and regulations to
increase the enrollment of pregnant women through the creation of new IND and NDA
laws, defining subpopulation of women, and expanding pregnancy registries.
First, IND and NDA’s must require an assessment in pregnant women prior to
approval of the drug or biologic. Under the current law, the FDA has the authority to
require a pediatric assessment, which contains data adequate to assess safety and
efficacy. 164 This pediatric population mandate has contributed data on drug labels
“concerning the safe and effective use of more than 400 drugs in neonates, infants,
children, and adolescents.”165
An adoption of a similar law for an assessment in pregnant women prior to
approval, where scientifically appropriate, will increase evidence-based data. This law
will adopt testing protocols similar to the Pediatric Research Equity Act, including
allowing a waiver when a pregnant women assessment is not necessary. The pediatric
population is also categorized as a vulnerable population, yet this law has proved
successful in the ability to regulate and conduct clinical studies in pediatrics. Therefore, a
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similar law must be enacted to increase pregnant women in clinical research.
Second, the FDA should expand NDA and IND demographic reporting for
subgroups to include pregnant women and non-pregnant women. Federal regulations
require NDA’s to present effectiveness and safety data for important demographic
subgroups, specifically gender.166 One public comment to the FDA requested a definition
for subpopulations of women because “safety, pharmacokinetic, and efficacy data for
pregnant women should be presented separately from data for women who are not
pregnant.”167 However, the FDA declined to define subpopulations of women because “it
is not necessary…and usually pregnant women would only participate in clinical trials
intended specifically to study drug effects during pregnancy. The data generated from
such trials would, therefore, reflect use in this subpopulation of women.”168
The FDA should not decline to define subpopulations of women. The response
that data generated from trials that were specifically intended to study drug effects during
pregnancy is unsatisfactory based on today’s clinical trial landscape. Manufacturers and
the NIH are not conducting any trials in pregnant women to determine safety and efficacy
of drugs for chronic conditions such as diabetes and hypertension. Trials do not reflect a
breakdown of subpopulations for pregnant and non-pregnant. A requirement for a trial to
provide a women subpopulation is an appropriate response.
Lastly, Congress should expand the law to require pregnancy exposure registries
as a condition for approval for drugs in Category C, D, or X. As part of the expansion of
pregnancy exposure registries, the FDA should also issue guidance for manufacturers to
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become involved in the process by creating a portal for patients to enroll in a registry for
a product that is C, D or X. The FDA has the authority to require drug makers to study
the effects of newly approved medicines on pregnant and nursing women and newborn
infants, therefore the FDA must decide if the manufacturer should be required to set up a
pregnancy registry as a condition of approval.169
The FDA does not maintain the pregnancy registries, although there is a partial
list available on the OWH website. The law must require registries as a condition of
approval for Category C, D and X drugs as well as postmarketing surveillance. 170 The
expansion of this law allows for the FDA to require the collection of data in pregnant
women with the ultimate goal to decrease birth defects and promote awareness about the
importance of obtaining evidence-based medicine in pregnancy.
CONCLUSION
Awareness, education, incentive programs, or mandatory requirements from
DHHS will resolve the conflict of obtaining evidence-based data for prescriptions taken
during pregnancy as well as increase enrollment of pregnant women in clinical trials. The
harms of inadequate clinical research fall on pregnant women, fetuses, and children. Over
the past twenty years, women may participate in clinical research, but as the current
clinical trial landscape demonstrates, researchers and industry do not enroll or recruit
pregnant women. Pregnant women must be afforded the same rights, advocacy, and data,
and it is up to the industry and government to provide a different approach and ensure
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improved methodologies to clinical research.
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